SciencePediaAs we age, our immune system presents a paradox: it becomes both over-active, fostering a state of chronic low-grade inflammation, and under-responsive, struggling to fight off new infections or benefit from vaccines. A central explanation for this decline, known as immunosenescence, lies deep within our bone marrow in a phenomenon called myeloid skew. This fundamental shift in the production line of our blood and immune cells, favoring the rapid-response myeloid lineage at the expense of the adaptive lymphoid lineage, has profound consequences for our health. But what drives this imbalance? Is it a flaw in the master stem cells themselves or in the environment they inhabit?
This article dissects the science behind myeloid skew, offering a comprehensive look at this critical aspect of aging. Across two main chapters, you will gain a clear understanding of this complex biological process.
Imagine the bone marrow is a bustling, high-tech factory. This factory, working tirelessly day and night, is responsible for producing all the cells in your blood. At its heart are the master artisans, the hematopoietic stem cells (HSCs). These remarkable cells hold the blueprint for every type of blood cell, from the oxygen-carrying red blood cells to the diverse soldiers of your immune system. Each time an HSC divides, it faces a profound choice: it can create a perfect copy of itself, ensuring the factory's workforce never depletes, or it can commit to a production line, spawning daughter cells that will mature into specialized workers. The two main production lines of the immune system are the myeloid lineage—the rapid-response infantry like neutrophils and macrophages—and the lymphoid lineage—the highly specialized intelligence officers like B and T cells. For most of your life, the factory maintains a beautiful, dynamic balance between these outputs. But as the factory and its artisans age, a curious and consequential shift begins to occur. The production line starts to tilt.
Before we explore the changes of aging, we must appreciate a subtle and beautiful truth: not all HSCs are created equal. If you could line up ten HSCs, all looking identical under a microscope and all bearing the same surface markers that shout "I am a stem cell!", you might assume they are interchangeable. But you would be wrong. Biology, it turns out, cherishes individuality. Through a series of elegant experiments involving transplanting single HSCs into mice, scientists discovered that these cells possess innate "flavors" or biases. Even in a young, healthy mouse, some HSCs are intrinsically predisposed to produce more myeloid cells, some have a lymphoid preference, and others are wonderfully balanced.
This isn't due to changes in their genetic code, their DNA. Rather, it's a matter of epigenetics—the layer of instructions written on top of the DNA. Think of it as bookmarks, highlights, and sticky notes attached to the master blueprint. These epigenetic marks don't change the blueprint's text, but they dictate which pages are read and which are ignored. So, one HSC might have a "bookmark" near the myeloid chapter, predisposing it to read those instructions more readily. This inherent heterogeneity is not a flaw; it's a feature, providing a diverse and resilient workforce from the very beginning.
This delicate, diverse balance starts to falter with age. The factory's output begins to skew, consistently and systematically, towards the myeloid lineage at the expense of the lymphoid one. This phenomenon is known as myeloid skew or myeloid bias. The bone marrow, once a balanced producer, now churns out an excess of first-responder myeloid cells while neglecting the production of new, naïve B and T lymphocytes.
The consequence of this shift is profound. Your adaptive immune system, which relies on a fresh supply of naïve lymphocytes to recognize and fight new invaders, becomes weakened. It's like an army that stops training new recruits and only relies on its aging veterans. This contributes to the state of immunosenescence, explaining why the elderly are often more susceptible to new infections and respond less effectively to vaccines. The factory is still running, but its priorities have changed, leaving its host more vulnerable.
So, what causes this shift? Is the problem with the master artisans themselves—the HSCs—or with the factory they live in—the bone marrow niche? This is a classic "nature versus nurture" question at the cellular level, and scientists have devised clever experiments to find the answer.
Imagine a set of reciprocal transplants, a sort of cellular exchange program. First, you take an old, myeloid-biased HSC (the "old worker") and place it into a young, healthy bone marrow (the "new workshop"). You find that the old HSC, while its function might improve slightly in the pristine new environment, still produces a myeloid-biased output. This tells us a large part of the problem is cell-intrinsic; the aging worker carries its flawed work habits with it.
Next, you do the reverse: you take a young, pristine HSC (the "young worker") and place it into an old, dilapidated bone marrow (the "old workshop"). Astonishingly, the young HSC begins to misbehave. Influenced by its aged surroundings, it too starts to exhibit myeloid skew. This proves that a significant part of the problem is also cell-extrinsic; the aging environment actively corrupts the workers within it.
The verdict is clear: myeloid skew is the result of a conspiracy. It’s a combination of deterioration within the HSCs themselves and a toxic influence from their aging microenvironment.
Let's first look inside the aging HSC. The intrinsic defects are largely a story of accumulating epigenetic errors. Over a lifetime of divisions, the system of "bookmarks" on the DNA becomes messy. This is epigenetic drift.
A beautiful illustration of this comes from imagining what happens when one of the epigenetic "librarians"—an enzyme that adds or removes these marks—stops working. For example, the enzyme KDM6B has the job of removing a specific "STOP" signal (a histone mark called ) from the promoters of genes that drive lymphoid development. If KDM6B is lost due to a mutation, those crucial lymphoid genes, like PAX5, can never be fully activated. The "STOP" sign is stuck in place. The cell, unable to proceed down the lymphoid path, is shunted by default into the myeloid lineage.
This brings us to the most notorious culprits in age-related myeloid skew: mutations in the genes DNMT3A and TET2. These are the master writer and eraser of one of the most fundamental epigenetic marks, DNA methylation.
With age, mutations can arise that break one of these genes.
In both cases, these mutations give the HSC a powerful selective advantage. In the competitive environment of the bone marrow, the mutant HSC outcompetes its healthy neighbors. This is not because it works better, but because it's better at selfishly self-renewing. The probability of symmetric self-renewal () increases relative to symmetric differentiation (), such that the net change in stem cell number per division becomes positive ().
This leads to a phenomenon called Clonal Hematopoiesis of Indeterminate Potential (CHIP). A single mutant HSC can expand over decades to form a massive clone that dominates the blood production of an elderly individual. Since these mutations almost always favor the myeloid pathway, the result is a firehose of myeloid cells, drastically skewing the body's entire immune landscape.
Now let's turn to the "workshop," the aging bone marrow niche. The extrinsic story of myeloid skew can be summarized in one word: inflammaging. This is the chronic, low-grade, smoldering inflammation that permeates our tissues as we age. It's like a fire alarm that is stuck on, constantly blaring.
This alarm is broadcast via inflammatory signal molecules, or cytokines, such as Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF). These cytokines flood the bone marrow niche and act as a terrible influence on the HSCs. They bind to receptors on the stem cells and activate internal signaling pathways like NF-κB and p38 MAPK. These are ancient pathways, hard-wired for emergency response. Their activation flips a master switch inside the HSC, screaming a single, urgent command: "Emergency! Drop everything and make myeloid cells now!".
This chronic inflammatory signaling does two things simultaneously. First, it directly upregulates the key transcription factors for myelopoiesis, like PU.1 and C/EBPβ. Second, it actively suppresses lymphopoiesis. It can do this directly, by repressing lymphoid transcription factors, and indirectly, by damaging the niche cells that produce Interleukin-7 (IL-7), a cytokine absolutely essential for the survival and development of lymphoid progenitors. The neighborhood is not only screaming for more myeloid cells but is also actively starving the lymphoid production line.
This dual mechanism—an intrinsic decay of the cell's programming and an extrinsic pressure from a toxic environment—paints a grim picture of aging. But here lies the true beauty and unity of the system. The myeloid skew of aging is not some random, senseless decay. Instead, it is the pathological hijacking of a system that originally evolved for a very good reason: emergency myelopoiesis.
Imagine you get a serious bacterial infection. Your body needs to produce a massive wave of neutrophils and macrophages immediately to fight it off. It can't wait. It turns out that HSCs have their own built-in danger sensors, such as Toll-like Receptor 4 (TLR4). This receptor can directly recognize components of bacteria, like lipopolysaccharide (LPS). When an HSC directly detects LPS, it triggers an internal alarm—even without any cytokine signals from other cells—and immediately switches its production to the myeloid lineage.
Here, then, is the grand, unifying idea. The ability to rapidly skew production towards myeloid cells is a critical, life-saving feature of our immune system, designed for acute emergencies. The tragedy of aging is that the chronic inflammation of "inflammaging" tricks the system into thinking it is in a permanent state of emergency. The very mechanism designed to save us from acute infection becomes, when chronically activated, a driver of age-related decline. The myeloid skew of aging is not a new program, but an old one stuck on repeat—a beautiful, powerful sword that, with time, we can no longer put back in its sheath.
In the previous chapter, we dissected the beautiful and intricate machinery of hematopoiesis, the process that gives rise to our blood and immune cells. We saw how a single type of cell, the hematopoietic stem cell (HSC), holds the potential to become any of a dozen different finished products, from oxygen-carrying red blood cells to microbe-devouring neutrophils. But what happens when this exquisitely balanced factory develops a preference? When the assembly line begins to churn out one type of product at the expense of another? This phenomenon, myeloid skew, is far from an obscure detail of cell biology. It is a powerful, unseen architect that profoundly shapes our health, influencing how we age, how we fight infection, and even the health of our hearts.
Imagine an orchestra where, over the years, the string section gradually dwindles while the percussion section grows ever larger and louder. The music would still play, but its character would be fundamentally altered. This is a fitting analogy for what happens to our immune system as we age, a process known as immunosenescence. One of its central features is a steady, predictable shift in hematopoietic output: myeloid skew.
We’ve all observed that older individuals tend to be more susceptible to bacterial infections like pneumonia and often show a weaker response to vaccines, such as the annual flu shot. This isn’t just a matter of the body being "worn out." It's a direct consequence of myeloid skew. With age, our HSCs develop an intrinsic bias, favoring the production of myeloid cells (like neutrophils and monocytes) over lymphoid cells (the T and B cells that form our adaptive immunity). The result is an immune system that is over-represented by the "first responders" of the innate army, while the "special forces"—the naive T and B cells that learn to recognize and remember new threats—become scarce. Without a diverse and plentiful pool of these naive lymphocytes, our ability to mount a robust defense against novel pathogens or to build a strong memory from a vaccine is dangerously compromised.
This isn't a simple, passive decline. It is an active, programmed process driven by changes both inside the stem cells and in their surrounding environment, the "niche." Over a lifetime, our HSCs accumulate epigenetic "scars"—subtle chemical marks on their DNA and associated proteins. For instance, the genes that pilot cells toward a lymphoid fate, such as Ebf1 and Pax5, become progressively silenced by DNA hypermethylation, while genes that command a myeloid fate, like Spi1, become more active. Simultaneously, the bone marrow niche itself ages. It begins to produce less of the supportive signals that nurture lymphoid progenitors, like the chemokines CXCL12 and SCF, and the critical growth factor IL-7. To make matters worse, a state of chronic, low-grade inflammation, dubbed "inflammaging," sets in, bathing the stem cells in signals like IL-1β and TNF-α that actively push them down the myeloid path. In essence, the stem cell and its home are locked in a feedback loop that continually reinforces the myeloid-biased state, fundamentally altering the score of our immune symphony.
For a long time, myeloid skew was viewed primarily through the lens of immunology and aging. But one of the great joys of science is discovering connections where none were suspected. It turns out that this shift in blood production is a key player in one of the leading causes of death worldwide: cardiovascular disease.
Within our aging bodies, a sort of Darwinian evolution is constantly at play within our HSC population. Occasionally, a single HSC acquires a somatic mutation—a typo in its genetic code—that gives it a competitive advantage. This mutant stem cell can then outgrow its neighbors, leading to a clonally expanded population of blood cells that all share the same mutation. When this occurs in the absence of overt blood cancer, it is known as Clonal Hematopoiesis of Indeterminate Potential, or CHIP. The genes most commonly mutated in CHIP, such as TET2, DNMT3A, and ASXL1, are often epigenetic regulators whose disruption frequently results in a strong myeloid skew.
Here is the stunning connection: individuals with CHIP have a significantly higher risk of heart attack and stroke. The very same mutations that cause myeloid skew also "prime" the resulting myeloid cells—the monocytes and macrophages—to be hyper-inflammatory. When these cells are recruited to atherosclerotic plaques in the walls of our arteries, they pour fuel on the fire. For example, macrophages with a TET2 mutation show heightened activity of a molecular machine called the NLRP3 inflammasome, leading to massive production of the inflammatory cytokine IL-1β. Another CHIP driver, the JAK2 mutation, leads to neutrophils that are more prone to extruding their DNA in web-like structures called NETs, which can promote thrombosis, or blood clotting. Myeloid skew, in the form of CHIP, is therefore not a bystander but an active participant in atherosclerosis, revealing a deep mechanistic unity between the health of our bone marrow and the health of our heart.
This connection is so robust that we can even model it quantitatively. By tracking the frequency of a mutant clone in the blood over time—for example, a TET2-mutant clone—we can use principles of population dynamics to estimate its fitness advantage and predict the progressive skewing of the myeloid-to-lymphoid ratio. What begins as a subtle change in the bone marrow becomes a measurable and predictable risk factor for future disease.
Myeloid skew is not a one-way street dictated solely by the stem cell. It is a dynamic dialogue between the cell and its environment. We can visualize this beautifully through the elegant logic of competitive transplantation experiments. If we take a mixture of young and aged HSCs and transplant them into a host, we can watch the aged HSCs' intrinsic myeloid bias play out in real time. Even though they start at a 50/50 ratio with their young competitors at the stem cell level, the blood system they produce becomes rapidly dominated by myeloid cells derived from the aged HSCs, while the lymphoid compartment is preferentially supplied by the young cells. These experiments provide definitive proof that the bias is a cell-intrinsic property that unfolds predictably over time.
But what if this "intrinsic" property could be extrinsically programmed? Astonishingly, it can. Our environment, and even the microbes that live within us, can reach into our bone marrow and reshape our hematopoietic output. In a fascinating phenomenon known as "trained immunity," exposure to certain microbial components, such as the cell wall of a yeast, can leave a lasting epigenetic imprint on our HSCs. This molecular memory can reprogram them to favor myelopoiesis, essentially preparing the innate immune system for a future encounter. It's a remarkable discovery, showing that myeloid skew can be an adaptive response, a way for our deepest biology to learn from experience.
The power of the local environment, or "niche," is perhaps best illustrated by the sophisticated tools of modern biomedical engineering. When we try to create "humanized mice" by transplanting human HSCs into immunodeficient animals, the source of the HSCs matters. Adult HSCs mobilized from peripheral blood, for instance, are already somewhat myeloid-skewed compared to their more primitive counterparts from fetal liver or cord blood, and this bias is reflected in the blood system they generate in the mouse. But there's a deeper issue: the mouse bone marrow is a "foreign" niche for human cells. The molecular language of the murine stromal cells—the specific ligands and adhesion molecules—is often a poor match for the receptors on human HSCs. This mismatch in communication leads to aberrant signaling and, often, a pronounced myeloid skew that doesn't reflect normal human hematopoiesis.
The truly definitive proof of the niche's power comes from a brilliant experiment: what if we provide the human HSCs with a human home? By engineering a small, implantable "ossicle"—a piece of bone-like tissue grown from human stromal cells—we can create a human hematopoietic niche inside the mouse. Human HSCs that find their way to this human niche behave completely differently. They receive the correct, species-matched signals for adhesion (VCAM-1), retention (CXCL12), and fate decisions (Notch ligands). In this supportive human environment, the aberrant myeloid skew is corrected, and a balanced, multi-lineage blood system develops. This teaches us a profound lesson: a stem cell's destiny is a conversation, not a monologue.
Understanding a problem is the first step toward solving it. If myeloid skew is a central feature of aging and disease, can we learn to control it? The answer, excitingly, appears to be yes.
A direct and pragmatic application lies in vaccine design for older adults. We know their immune systems are myeloid-skewed and have fewer naive lymphocytes. A standard vaccine adjuvant might not provide a strong enough signal to get their attention. The solution is not to give up, but to design smarter, more potent adjuvants. Modern strategies combine multiple components to overcome specific age-related hurdles. A STING agonist can be used to robustly activate type I interferon pathways, which are critical for licensing dendritic cells to prime T-cell responses. This can be combined with other pattern recognition receptor agonists and delivery systems that ensure the vaccine components get to the lymph nodes and strongly activate the few naive cells that are available. We might even supplement this with short-term administration of cytokines like IL-7 to transiently boost the size and survival of the naive T cell pool. This is translational medicine at its finest: using fundamental knowledge to engineer a solution to a pressing clinical need.
The ultimate goal, of course, would be to turn back the clock on the stem cells themselves. Is rejuvenation possible? Emerging research suggests it might be. The chronically elevated activity of a signaling pathway called mTORC1 is a key driver of aging in many tissues, including the HSC compartment. By promoting protein synthesis and inhibiting autophagy (the cell's recycling system), high mTORC1 activity contributes to the metabolic stress, damaged components, and inflammatory state that lead to myeloid skew. Remarkably, treating aged animals with short-term, low-dose inhibitors of mTORC1 can have rejuvenating effects. This intervention re-activates autophagy, cleans up the cellular damage, quiets the inflammatory niche, and allows the aged HSCs to return to a healthier, more quiescent state. Functionally, this restores a more balanced lineage output, reducing myeloid bias and improving the stem cells' long-term ability to repopulate a blood system.
From a subtle shift in cellular statistics to a driving force in aging, heart disease, and immunity, myeloid skew stands as a testament to the interconnectedness of biology. It is a reminder that the health of our entire body can depend on the quiet decisions being made deep within our bones. By continuing to decipher the language of this unseen architect, we move ever closer to a future where we can not only understand but also guide its hand, preserving the symphony of our health for years to come.